Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs)

Joseph A. Blansfield, Lynda Choyke, Shane Y. Morita, Peter L. Choyke, James F. Pingpank, H. Richard Alexander, Geoffrey Seidel, Yvonne Shutack, Nargiza Yuldasheva, Michelle Eugeni, David L. Bartlett, Gladys M. Glenn, Lindsay Middelton, W. Marston Linehan, Steven K. Libutti

Research output: Contribution to journalArticle

143 Citations (Scopus)

Abstract

Background: von Hippel-Lindau (vHL) disease is an autosomal dominant syndrome associated with neoplasms in multiple organs, which includes the pancreas. Here, we report the greatest single center experience in patients with vHL pancreatic endocrine neoplasm (PNETs). Methods: Between December 1998 and November 2006, 633 patients with vHL were evaluated and those with PNETs were enrolled on a prospective protocol. Results: Overall, 108 vHL patients had PNETs (17%). Nine patients had metastatic disease (8.3%) from their PNET. Patients with lesions greater than 3 cm (n = 25) were more likely to develop metastases than patients with lesions less than 3 cm (n = 83) (P < .005). Thirty-nine patients underwent resection. Germline sequencing showed that 78% of patients with metastases (7/9) had exon 3 mutations compared with 46% of patients without metastases (32/98; P < .01). Tumor doubling time was calculated for the largest PNET. The group with metastases had an average tumor doubling time of 337 days (range, 180-463 days) compared with 2630 days (range, 103-9614 days) for those without metastases (P < .0001). Conclusions: By implementing a system of selective operative resection based on defined criteria, vHL patients with PNETs can be managed safely. For patients with small primary lesions (<3 cm), without a mutation of exon 3 and slow tumor doubling time (>500 days), a nonoperative approach may be appropriate for these nonfunctional neoplasms.

Original languageEnglish (US)
Pages (from-to)814-818
Number of pages5
JournalSurgery
Volume142
Issue number6
DOIs
StatePublished - Dec 2007
Externally publishedYes

Fingerprint

von Hippel-Lindau Disease
Primitive Neuroectodermal Tumors
Pancreatic Neoplasms
Pancreas
Neoplasms
Neoplasm Metastasis

ASJC Scopus subject areas

  • Surgery

Cite this

Blansfield, J. A., Choyke, L., Morita, S. Y., Choyke, P. L., Pingpank, J. F., Alexander, H. R., ... Libutti, S. K. (2007). Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery, 142(6), 814-818. https://doi.org/10.1016/j.surg.2007.09.012

Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). / Blansfield, Joseph A.; Choyke, Lynda; Morita, Shane Y.; Choyke, Peter L.; Pingpank, James F.; Alexander, H. Richard; Seidel, Geoffrey; Shutack, Yvonne; Yuldasheva, Nargiza; Eugeni, Michelle; Bartlett, David L.; Glenn, Gladys M.; Middelton, Lindsay; Linehan, W. Marston; Libutti, Steven K.

In: Surgery, Vol. 142, No. 6, 12.2007, p. 814-818.

Research output: Contribution to journalArticle

Blansfield, JA, Choyke, L, Morita, SY, Choyke, PL, Pingpank, JF, Alexander, HR, Seidel, G, Shutack, Y, Yuldasheva, N, Eugeni, M, Bartlett, DL, Glenn, GM, Middelton, L, Linehan, WM & Libutti, SK 2007, 'Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs)', Surgery, vol. 142, no. 6, pp. 814-818. https://doi.org/10.1016/j.surg.2007.09.012
Blansfield, Joseph A. ; Choyke, Lynda ; Morita, Shane Y. ; Choyke, Peter L. ; Pingpank, James F. ; Alexander, H. Richard ; Seidel, Geoffrey ; Shutack, Yvonne ; Yuldasheva, Nargiza ; Eugeni, Michelle ; Bartlett, David L. ; Glenn, Gladys M. ; Middelton, Lindsay ; Linehan, W. Marston ; Libutti, Steven K. / Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). In: Surgery. 2007 ; Vol. 142, No. 6. pp. 814-818.
@article{c939a61ab6a94faa946c8e8f570cc84f,
title = "Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs)",
abstract = "Background: von Hippel-Lindau (vHL) disease is an autosomal dominant syndrome associated with neoplasms in multiple organs, which includes the pancreas. Here, we report the greatest single center experience in patients with vHL pancreatic endocrine neoplasm (PNETs). Methods: Between December 1998 and November 2006, 633 patients with vHL were evaluated and those with PNETs were enrolled on a prospective protocol. Results: Overall, 108 vHL patients had PNETs (17{\%}). Nine patients had metastatic disease (8.3{\%}) from their PNET. Patients with lesions greater than 3 cm (n = 25) were more likely to develop metastases than patients with lesions less than 3 cm (n = 83) (P < .005). Thirty-nine patients underwent resection. Germline sequencing showed that 78{\%} of patients with metastases (7/9) had exon 3 mutations compared with 46{\%} of patients without metastases (32/98; P < .01). Tumor doubling time was calculated for the largest PNET. The group with metastases had an average tumor doubling time of 337 days (range, 180-463 days) compared with 2630 days (range, 103-9614 days) for those without metastases (P < .0001). Conclusions: By implementing a system of selective operative resection based on defined criteria, vHL patients with PNETs can be managed safely. For patients with small primary lesions (<3 cm), without a mutation of exon 3 and slow tumor doubling time (>500 days), a nonoperative approach may be appropriate for these nonfunctional neoplasms.",
author = "Blansfield, {Joseph A.} and Lynda Choyke and Morita, {Shane Y.} and Choyke, {Peter L.} and Pingpank, {James F.} and Alexander, {H. Richard} and Geoffrey Seidel and Yvonne Shutack and Nargiza Yuldasheva and Michelle Eugeni and Bartlett, {David L.} and Glenn, {Gladys M.} and Lindsay Middelton and Linehan, {W. Marston} and Libutti, {Steven K.}",
year = "2007",
month = "12",
doi = "10.1016/j.surg.2007.09.012",
language = "English (US)",
volume = "142",
pages = "814--818",
journal = "Surgery (United States)",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs)

AU - Blansfield, Joseph A.

AU - Choyke, Lynda

AU - Morita, Shane Y.

AU - Choyke, Peter L.

AU - Pingpank, James F.

AU - Alexander, H. Richard

AU - Seidel, Geoffrey

AU - Shutack, Yvonne

AU - Yuldasheva, Nargiza

AU - Eugeni, Michelle

AU - Bartlett, David L.

AU - Glenn, Gladys M.

AU - Middelton, Lindsay

AU - Linehan, W. Marston

AU - Libutti, Steven K.

PY - 2007/12

Y1 - 2007/12

N2 - Background: von Hippel-Lindau (vHL) disease is an autosomal dominant syndrome associated with neoplasms in multiple organs, which includes the pancreas. Here, we report the greatest single center experience in patients with vHL pancreatic endocrine neoplasm (PNETs). Methods: Between December 1998 and November 2006, 633 patients with vHL were evaluated and those with PNETs were enrolled on a prospective protocol. Results: Overall, 108 vHL patients had PNETs (17%). Nine patients had metastatic disease (8.3%) from their PNET. Patients with lesions greater than 3 cm (n = 25) were more likely to develop metastases than patients with lesions less than 3 cm (n = 83) (P < .005). Thirty-nine patients underwent resection. Germline sequencing showed that 78% of patients with metastases (7/9) had exon 3 mutations compared with 46% of patients without metastases (32/98; P < .01). Tumor doubling time was calculated for the largest PNET. The group with metastases had an average tumor doubling time of 337 days (range, 180-463 days) compared with 2630 days (range, 103-9614 days) for those without metastases (P < .0001). Conclusions: By implementing a system of selective operative resection based on defined criteria, vHL patients with PNETs can be managed safely. For patients with small primary lesions (<3 cm), without a mutation of exon 3 and slow tumor doubling time (>500 days), a nonoperative approach may be appropriate for these nonfunctional neoplasms.

AB - Background: von Hippel-Lindau (vHL) disease is an autosomal dominant syndrome associated with neoplasms in multiple organs, which includes the pancreas. Here, we report the greatest single center experience in patients with vHL pancreatic endocrine neoplasm (PNETs). Methods: Between December 1998 and November 2006, 633 patients with vHL were evaluated and those with PNETs were enrolled on a prospective protocol. Results: Overall, 108 vHL patients had PNETs (17%). Nine patients had metastatic disease (8.3%) from their PNET. Patients with lesions greater than 3 cm (n = 25) were more likely to develop metastases than patients with lesions less than 3 cm (n = 83) (P < .005). Thirty-nine patients underwent resection. Germline sequencing showed that 78% of patients with metastases (7/9) had exon 3 mutations compared with 46% of patients without metastases (32/98; P < .01). Tumor doubling time was calculated for the largest PNET. The group with metastases had an average tumor doubling time of 337 days (range, 180-463 days) compared with 2630 days (range, 103-9614 days) for those without metastases (P < .0001). Conclusions: By implementing a system of selective operative resection based on defined criteria, vHL patients with PNETs can be managed safely. For patients with small primary lesions (<3 cm), without a mutation of exon 3 and slow tumor doubling time (>500 days), a nonoperative approach may be appropriate for these nonfunctional neoplasms.

UR - http://www.scopus.com/inward/record.url?scp=36549022020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36549022020&partnerID=8YFLogxK

U2 - 10.1016/j.surg.2007.09.012

DO - 10.1016/j.surg.2007.09.012

M3 - Article

VL - 142

SP - 814

EP - 818

JO - Surgery (United States)

JF - Surgery (United States)

SN - 0039-6060

IS - 6

ER -